CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Beijing Tri Prime Gene Pharmcutcl Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Beijing Tri Prime Gene Pharmcutcl Co Ltd
No.1 Jinyuan Road
Daxing Economical Development Zone
Phone: +86 1060219175p:+86 1060219175 BEIJING, BEJ  102600  China Ticker: 837344837344
Business Summary
Beijing Tri Prime Gene Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of biological medicine. The Company's main products include human interferon alfa 1b powder for injection, human interferon alfa 1b injection, human interferon alfa 1b eye drops and recombinant human interferon alfa 1b spray. The Company's brand name is Yundesu. Its products are mainly used to treat viral diseases and malignant tumors such as viral hepatitis, viral pneumonia, condyloma acuminatum, viral keratitis, hairy cell leukemia, chronic myeloid leukemia and melanoma. The Company primarily conducts its businesses in the domestic market.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
General Manager YongqingCheng

General Information
Number of Employees: 260 (As of 12/31/2023)
Outstanding Shares: 121,810,000 (As of 12/31/2023)
Shareholders: 6,775
Stock Exchange: BJS
Fax Number: +86 1061253368


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024